From: Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
Exon
Codon
Hot spot site
Amino acid
No. of patients
%
2
12
24
40.6
c.34 G>A
p.Gly12Ser
1
1.6
c.35 G>A
p.Gly12Asp
15
25.4
c.35 G>T
p.Gly12Val
7
11.8
c.35 G>C
p.Gly12Ala
13
4
6.7
c.37_39 dupl
p.Gly13 dupl
c.37
-
c.38 G>A
p.Gly13Asp
3
5